Istituto Oncologico Veneto Irccs
Clinical trials sponsored by Istituto Oncologico Veneto Irccs, explained in plain language.
-
New hope for elderly colorectal cancer patients: triple therapy shows promise
Disease control OngoingThis study looks at how well a combination of three drugs—capecitabine, oxaliplatin, and bevacizumab—works as a first treatment for elderly patients (70 and older) with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if this approach can delay c…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy shows promise for rare lung cancer
Disease control OngoingThis study tests whether giving a combination of the immunotherapy drug pembrolizumab and chemotherapy before surgery can help people with a rare cancer called pleural mesothelioma. The trial involves 41 adults with early-stage disease that can be surgically removed. The main goa…
Phase: PHASE2 • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Simple 8-Question test may predict survival in elderly cancer patients
Knowledge-focused OngoingThis study looks at whether a quick, 8-item screening tool called G8 can help predict survival and severe side effects from treatment in elderly patients (70 years and older) with metastatic colorectal cancer. The goal is to find a simple way to identify which older patients are …
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New imaging technique could reveal how brain tumors hide from the immune system
Knowledge-focused OngoingThis study looks at how aggressive brain tumors (gliomas) suppress the immune system. Researchers will use special MRI and PET scans to track immune cells and iron levels in the tumor. The goal is to find better ways to measure immune suppression, which could help develop new tre…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC